logo-loader

ImpediMed achieves milestone coverage of more than 20 million lives for L-Dex U400

Last updated: 11:00 14 Mar 2012 AEDT, First published: 10:00 14 Mar 2012 AEDT

no_picture_pai

ImpediMed (ASX: IPD) has reached a milestone in the coverage of its L-Dex u400 device to 23.4 million lives within the United States.

L-Dex U400 aids in the clinical assessment of unilateral lymphoedema of the arm in females.

Building on the momentum of this expansion in coverage are two new plans, a key Health Maintenance Organization (HMO) and another Third Party Administrator (TPA).

New clinical guidelines developed by the HMO provide a perspective on breast cancer survival, aimed at improving the patient’s quality of life, wellbeing and longevity.

Breast cancer-related lymphoedema is one of the topics addressed in the guidelines.

These guidelines will come into effect in one key centre of the HMO in May 2012, and will be rolled out to other centres over the coming year.

ImpediMed has not yet negotiated supply agreements for L-Dex U400 with this HMO.

Meanwhile, the TPA offers a program that covers a fully insured product and administering self-funded plans, with business in six states.

These new plans follow last month’s announcement of the passing of the Patient Protection and Affordable Care Act.

The Act makes certain indigenous tribes and organisations eligible to access the health plans for federal employees.

As a result of the passing of the Act, ImpediMed expects an increase in covered lives for federal healthcare plans from May 1, 2012.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

9 hours, 49 minutes ago